BioSpace News Archive

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics.

MindMaze, the global leader in digital neuro-therapeutics solutions, building a universal platform for neurological recovery and care, announced the appointment of Kevin J. Gallagher as Chief Financial Officer.

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), will report financial results for its fourth quarter of fiscal year 2021, ended August 31, 2021, on Tuesday, November 23, 2021, before the open of the market.

OncoOne, and GenScript ProBio today announced that the companies have entered into an agreement for the cell line development, drug substance and drug product manufacturing of therapeutic and diagnostic monoclonal antibodies (mAbs) directed against the promising immuno-oncology target, oxidized macrophage migration inhibitory factor (oxMIF).

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for 82 research and training grants totaling $47.4 million.

Amgen announced the awarding of a one-time $25,000 grant to the Bath Institute of Rheumatic Diseases as part of the Understanding Psoriatic Disease Leveraging Insights for Treatment Innovation Challenge.

Pressure BioSciences, Inc. reported financial results for the third quarter ended September 30, 2021, provided a business update, and offered guidance for an expected strong 2022.

Novavax, Inc. (Nasdaq: NVAX), today announced that European Medicines Agency (EMA) has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax’ COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid™.

Eli Lilly and Company (NYSE: LLY) will participate in the fourth annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30, 2021.

OX2 Therapeutics, Inc., a privately held Minneapolis based company, announced today encouraging early results from phase 1 human trials of their new cancer treatment.